Author

Venkata D. Yellapantula

Memorial Sloan Kettering Cancer CenterORCID 0000-0003-1592-7741Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Assay:whole-exome sequencing· 2 Assay:whole-genome sequencing· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Adrienne HellandiD· 1 shared Ahmet A. Kurdoglu· 1 shared Ahmet DoǧaniD· 1 shared Ajai ChariiD· 1 shared Alex Blanski· 1 shared Alexander M. LesokhiniD· 1 shared Andrea Donnelly· 1 shared Andriy DerkachiD· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Adrienne HellandORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

GenomicsNature CommunicationsPeer-reviewedAug 27, 2021

Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma

Kylee H. Maclachlan, Even Holth Rustad, Andriy Derkach…·Francesco Maura

This study shows copy number signatures predict chromothripsis in multiple myeloma and link to poor clinical outcomes using whole genome and exome sequencing data.

49 citationstop 3%

humanwhole-genome sequencing

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintAug 2, 2021

Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study

Sheri Skerget, Daniel Peñaherrera, Ajai Chari…·Jonathan J. Keats

The paper identifies genomic subtypes of multiple myeloma using the MMRF CoMMpass study and finds that 25.5% of patients transition to a high-risk expression subtype at progression, which expresses immunotherapy targets.

19 citations

humanwhole-exome sequencing

𝕏 PostBluesky